Start with the basics
Raleigh peptide therapy,
minus the hard sell.
A plain-language guide to understanding the medicine, checking the care, and asking about the bill before a visit in Raleigh.
First, get the exact name.
The phrase peptide therapy can sound as though it names just one treatment. Begin with three questions: which medicine, which health problem, and who will assess me?
Peptides are small chains made of the building blocks found in proteins.
The word peptide alone does not establish that a product is safe or lawful.
Ask for the name in writing. Keep it beside the reason for the treatment. That is a firmer starting point than a promise about feeling better.
Separate these kinds of product.
The Food and Drug Administration (FDA) conducts drug reviews for specific products and uses.
An approved medicine
On September 26, 2026, semaglutide (Ozempic) and tirzepatide (Mounjaro) had FDA approval to control blood sugar for patients with type 2 diabetes.
By that same date, FDA approval also covered semaglutide (Wegovy) and tirzepatide (Zepbound) for losing weight and maintaining that loss.
Ask the person writing your prescription which product they mean and what health problem it would treat. A familiar ingredient name leaves that question open.
A compounded medicine
In compounding, a doctor or pharmacist may prepare medicine to fit one particular patient’s needs.
Compounded medicines remained unapproved by FDA on September 26, 2026.
These medicines reach the market without FDA first checking safety, quality, or effectiveness.
Compounding can be lawful under the rules recorded September 26, 2026.
FDA says compounding may suit a patient whose medical needs an approved medicine cannot meet, or when that medicine is unavailable.
Under the rules recorded September 26, 2026, a pharmacy or doctor cannot regularly make near-copies of a medicine already available as a ready-made product.
This limit concerns medicines made to order, rather than generic medicines already approved by FDA.
For a pharmacy preparing medicine for an identified patient, the copy limit has an exception.
The person writing the prescription must decide that a change in the pharmacy-made medicine makes a significant difference for that patient.
Ask how the pharmacy would alter your medicine and what that difference would mean for you.
A cheaper price, by itself, cannot justify this exception.
A product labeled for research
FDA warns that research-labeled weight-loss drugs offered for human use have unknown quality and may cause harm, as of September 26, 2026.
Treat that wording as a reason to pause. Ask a licensed doctor or other person treating you about the actual product before considering it as a care option.
In Raleigh, start with the state check.
When you are in North Carolina, the Medical Board generally expects the person treating you online to hold a North Carolina licence, as of September 28, 2026, with a few limited exceptions.
Request the treating person’s full name, plus the name of the pharmacy filling your prescription and handing or sending you the medicine. If another pharmacy makes it, ask for that name too. Use the names to check their licences in the next chapter.
Endnotes for this chapter
- FDA: semaglutide product label
The approved product’s uses; a label describes the product it belongs to.
- FDA: tirzepatide product label
Product-specific uses in the FDA label.
- FDA: what compounding means
How a pharmacy-made medicine differs from a finished approved product.
- FDA: limits on pharmacy-made copies
How the copy rules apply when national supply recovers.
- FDA: concerns about weight-loss products
Research labels, product quality, and the limits of compounding.
- Medical Board: online care in North Carolina
The patient’s location and the state licence check.